Häberle Lothar, Fasching Peter A, Brehm Barbara, Heusinger Katharina, Jud Sebastian M, Loehberg Christian R, Hack Carolin C, Preuss Caroline, Lux Michael P, Hartmann Arndt, Vachon Celine M, Meier-Meitinger Martina, Uder Michael, Beckmann Matthias W, Schulz-Wendtland Rüdiger
Department of Gynecology and Obstetrics, University Breast Center for Franconia, Erlangen University Hospital, Germany, Friedrich Alexander University of Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
Biostatistics Unit, Department of Gynecology and Obstetrics, Erlangen University Hospital, Erlangen, Germany.
Int J Cancer. 2016 Nov 1;139(9):1967-74. doi: 10.1002/ijc.30261. Epub 2016 Jul 19.
Although mammography screening programs do not include ultrasound examinations, some diagnostic units do provide women with both mammography and ultrasonography. This article is concerned with estimating the risk of a breast cancer patient diagnosed in a hospital-based mammography unit having a tumor that is visible on ultrasound but not on mammography. A total of 1,399 women with invasive breast cancer from a hospital-based diagnostic mammography unit were included in this retrospective study. For inclusion, mammograms from the time of the primary diagnosis had to be available for computer-assisted assessment of percentage mammographic density (PMD), as well as Breast Imaging Reporting and Data System (BIRADS) assessment of mammography. In addition, ultrasound findings were available for the complete cohort as part of routine diagnostic procedures, regardless of any patient or imaging characteristics. Logistic regression analyses were conducted to identify predictors of mammography failure, defined as BIRADS assessment 1 or 2. The probability that the visibility of a tumor might be masked at diagnosis was estimated using a regression model with the identified predictors. Tumors were only visible on ultrasound in 107 cases (7.6%). PMD was the strongest predictor for mammography failure, but age, body mass index and previous breast surgery also influenced the risk, independently of the PMD. Risk probabilities ranged from 1% for a defined low-risk group up to 40% for a high-risk group. These findings might help identify women who should be offered ultrasound examinations in addition to mammography.
尽管乳腺钼靶筛查项目不包括超声检查,但一些诊断科室确实为女性同时提供乳腺钼靶和超声检查。本文关注的是估计在医院乳腺钼靶科室被诊断出患有乳腺癌的患者,其肿瘤在超声检查中可见但在乳腺钼靶检查中不可见的风险。本回顾性研究纳入了一家医院诊断性乳腺钼靶科室的1399例浸润性乳腺癌女性患者。为纳入研究,必须有初次诊断时的乳腺钼靶片,以便进行计算机辅助评估乳腺钼靶密度百分比(PMD)以及乳腺影像报告和数据系统(BIRADS)对乳腺钼靶的评估。此外,作为常规诊断程序的一部分,整个队列的超声检查结果均可用,无论患者或影像特征如何。进行逻辑回归分析以确定乳腺钼靶检查失败的预测因素,定义为BIRADS评估为1或2。使用带有已确定预测因素的回归模型估计肿瘤在诊断时可能被掩盖的可见性概率。仅在107例(7.6%)病例中肿瘤仅在超声检查中可见。PMD是乳腺钼靶检查失败的最强预测因素,但年龄、体重指数和既往乳腺手术也独立于PMD影响风险。风险概率范围从定义的低风险组的1%到高风险组的40%。这些发现可能有助于识别除乳腺钼靶检查外还应接受超声检查的女性。